Merrimack CEO, CFO bow out, months after last clinical drug fizzles

Two months ago, Merrimack was forced to abandon its last drug in clinical trials, after an early-stage study showed that treatment with the drug, MM-310, was cumulatively toxic to patients, despite trial protocol amendments. On Monday, the ex-Sanofi executive the Cambridge, Massachusetts-based company ushered in 2017 to revive its fortunes departed.